BEAM - BEAM

Beam Therapeutics

BEAM THERAPEUTICS INC

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Eli Lilly

Analyst Color

Biotech

Large Cap

News

Downgrades

Health Care

Analyst Ratings

General

BEAM

CRSP

EDIT

NTLA

VERV

Lilly&#39;s Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly&#39;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Ark Invest Cathie Wood

Equities

ARKF

ARKK

ARKQ

ARKW

ARKX

AVDX

CRWD

CRWV

GTLB

KTOS

PLTR

RBLX

Cathie Wood&#39;s Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab

Display,Of,Stock,Market,Quotes

Intraday Update

Markets

Movers

Trading Ideas

CLSK

ERAS

MVST

PCRX

QURE

RCKT

REPL

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

Press Releases

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Earnings

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Legal

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical  Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Biohaven

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

ARS Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Guggenheim

Wells Fargo

Barclays

HC Wainwright & Co.

B of A Securities

Comments

Beam Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell